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Objectives: Market access entry agreements (MAA) are vital to access the Italian 
Market. MAAs, monitored by an AIFA registry, are divided into outcome based (cost-
sharing) and non-outcome based (risk-sharing and payment-by-results) agreements. 
The objective is to understand the MAA adoption, evolution and utilization vari-
ability among Therapeutic Areas. MethOds: The desk-based research was carried 
out by integrating different information sources, from AIFA and Gazzette Ufficiali 
to Regional HTA studies. Data was gathered for all the 82 products/indications 
belonging to an open registry signed up to a MAA since January 2006 up until April 
2015. Results: 59% products/indications have an outcome based MAA, 33% a 
non-outcome based and 1% both. A third of outcome based and a quarter of non-
outcome based MAAs have an additional volume agreement or spending cap. A 
maximum peak of 30 products/indications with MAA is recorded in 2014, compared 
to an annual average of 8. In 2006-2007 cost-sharing MAAs were predominantly 
adopted; in 2008-2011, outcome based MAAs were negotiated in approximately half 
of the cases (57%), becoming since 2012, the preferred conditional reimbursement 
scheme (78%). Focusing on Antineoplastic products, Leukemia drugs have only non-
outcome based agreements, Lymphoma, Melanoma, Breast, Colorectal and Ovary 
Cancer drugs have a prevalence of outcome based, whereas Renal Cell and Lung 
Cancer drugs have both. cOnclusiOns: Throughout the years there has been an 
increase in the adoption of a MAAs as they are considered a valuable strategy to 
manage payer budget impact and drug clinical benefit uncertainties. Since their 
introduction, the choice of MAA schemes utilized has witnessed an evolution, with 
an increasing preference for outcome based MAAs, though often applied together 
with additional financial saving schemes. Due to the model adoption variability of 
MAAs within the Therapeutic Areas, the study of their structure plays a key role in 
accessing the Italian Market.
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Objectives: We assessed NHS progress between 2004/5 and 2011/12 in reducing 
inequality in healthcare access and outcomes, with the aim of developing the first 
systematic approach to monitoring socioeconomic inequalities in NHS access and 
outcomes. MethOds: Indicators of healthcare access and outcomes at different 
stages of the patient pathway were constructed for all English small areas (2001 
LSOAs) from 2004/5 to 2011/12 using GMS, QOF, HES and ONS mortality and popula-
tion data – (1) GP supply: full time equivalent (FTE) GPs per 100,000 population, need-
weighted adjustment, (2) primary care quality: quality and outcomes framework 
performance, weighted by public health impact, (3) hospital waiting time: days from 
referral-to-treatment, allowing for patient-level casemix, (4) post-hospital mortality: 
12-month mortality after discharge, allowing for patient-level casemix, (5) amenable 
mortality: deaths from causes amenable to health care per 100,000 population, indi-
rectly age-sex-standardised. Slope and relative indices of inequality were calculated 
through small-area-level regression using all 32,482 Index of Multiple Deprivation 
2010 ranks, with regression-based tests of change over time. Results: Nationally, 
all unadjusted relative indices of inequality fell from 2004/5 to 2011/12 (with 95% 
CIs in brackets, where negative indices represent “pro-poor” inequality): (1) for GP 
supply from -2.2% [-2.9% to -1.6%] to -9.5% [-10.2% to -8.8%], (2) for primary care 
quality from 4.1% [3.6% to 4.6%] to 1.1% [0.6% to 1.6%], (3) for hospital waiting time 
from 3.2% [2% to 4.4%] to 2.7% [1.5% to 3.8%], (4) for post-hospital mortality from 
0.6% [2.3% to -1.2%] to -4.5% [-2.6% to -6.4%], and (5) for amenable mortality from 34% 
[36.5% to 31.4%] to 11.9% [14.6% to 9.2%]. cOnclusiOns: Socioeconomic inequal-
ity in healthcare access and outcomes in the English NHS reduced between 2004/5 
and 2011/12 in both relative and absolute terms on all our indicators (unadjusted), 
though all indicators except GP supply and post-hospital mortality continue to 
exhibit “pro-rich” inequality.
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Objectives: Risk minimization interventions (RMIs) implemented by drug manu-
facturers aim at optimizing the benefit-risk of medicines when important safety 
concerns related to product have been identified. In some situations, strict RMIs, 
such as controlled distribution programs or mandatory certification, may be 
required. Although aiming to improve patient’s safety, RMIs could be costly, time-
consuming, challenging and therefore, generate an undue burden on stakeholders. 
In some instances, regulatory agencies request that burden of RMIs be evaluated 
but no methodological guidance is available. The objective of the present study is 
to identify current methodologies used to evaluate the utility and burden associ-
ated with RMIs and to identify methodological gaps. MethOds: A non-systematic 
literature review was conducted using Medline and Embase in order to identify 
relevant publications that include an assessment of the utility and/or burden of 
RMI. Pragmatic searches using Google and Google Scholar search engines com-
pleted this analysis. Regulatory agencies websites were also consulted to identify 
potential existing guidelines related to the evaluation of the burden associated 
with RMIs. Results: A total of 362 relevant publications were identified in the 
literature. Among the methods used, surveys and focus groups appeared to be the 
most frequent as they allow to gather participants’ opinions providing a better 
understanding of the burden and potentially identifying optimization opportu-
nities. Mixed-method evaluations were also currently employed as they include 
guide their evaluation and use. While a need to stimulate pharmaceutical inno-
vation is widely recognized, cost containment is significant in decision-making. 
The objective of this research is to identify how members of the EU5 assess the 
innovative value of pharmaceuticals; understand the policies surrounding their 
market access and highlight potential drivers. MethOds: We assessed publicly 
available country guidelines and regulations to understand the evaluation and 
reimbursement process for innovative medicines. Findings were considered in 
light of definitions of innovation, market access conditions, reimbursement agree-
ments and sources of funding. Results: Across the EU5, definitions for innova-
tive medicines vary. In Italy, the approach involves an algorithm which forms the 
basis of the assessment and reimbursement process for innovative medicines at 
national level. In Spain, although innovation is considered alongside clinical and 
economic parameters in the evaluation of drugs, there are no special considera-
tions for reimbursement. France and Germany are both found to value innovation 
as a core criterion in the standard appraisal process with opportunities to facilitate 
market access in France and with prospects for price negotiations in Germany. In 
the UK, innovation is included as a modifying factor; however, the recently intro-
duced Early Access to Medicines Scheme, allows the UK to present a landscape 
facilitating the development of innovative medicines. cOnclusiOns: There are 
similarities and differences in the approaches used by the EU5 country members 
in their assessment and reimbursement of innovative medicines. While in some 
countries, innovative medicines benefit from lowered hurdles for market access; 
in other countries, innovation proves less impactful.
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Objectives: Patient Access Schemes (PAS) are agreed between pharmaceutical 
companies and the Department of Health (DoH, with input from National Institute 
of Health and Care Excellence [NICE]) that enable companies to offer discounts 
or rebates that reduce the cost of a drug. PAS proposals are made in the context 
of a NICE technology appraisal, with the aim of improving cost-effectiveness to 
enable a positive NICE recommendation. This research aims to systematically ana-
lyse all PASs for NICE- approved technologies with respect to the type of scheme 
agreed, indication, company and how these have varied over time. MethOds: 
Publically available technologies with approved PASs were identified from the NICE 
website and the date, treatment, indication, company, and type of scheme were 
extracted. Results: 49 PAS were identified involving 25 different companies. 51% 
(25/49) were for oncology medicines, 16% (8/49) rheumatology, 12% (6/49) ophthal-
mology, 6% (3/49) MS, and 14% (7/49) other. 76% (37/49) of PASs were simple dis-
counts, 14% (7/49) for free stock, 6% (3/49) dose caps, 2% (1/49) rebates, and 2% (1/49) 
response schemes. An average of 5.4 new PASs are agreed every year, but these have 
risen from 3 between 2007-2008 to 23 in 2013-2014. There is also a notable time trend 
in the type of PAS, with 97% (32/33) of PASs agreed since November 2011 being simple 
discounts versus only 31% (5/16) of those agreed beforehand. cOnclusiOns: PASs 
have been utilised by many pharmaceutical companies to help gain NICE approval 
primarily in oncology. Their utilisation has notably increased in recent years along-
side a very strong trend to almost exclusively be simple discount schemes, perhaps 
reflecting DoH aversion to managing more complex schemes. Nevertheless, the 
recent dose capping PAS agreed with GSK for Tafinlar in October 2014, illustrate that 
other types of schemes will still be considered acceptable by the DoH.
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Objectives: IVIgs are used off-label in a number of patients with rare diseases 
which is thought to be mostly responsible for their increasing use. We propose 
here to describe the market access framework set in the EU5 for IVIgs’ off-label use 
and determine if the level of evidence supporting off-label use influences its fund-
ing. MethOds: A literature review has been carried out in May 2015 using Pubmed 
and Datamonitor databases as well as websites of European Health authorities 
using the following terms: [off-label use OR unlicensed] AND [intravenous immuno-
globulin] AND [funding OR reimbursement]. Results: Despite its common practice, 
there is little regulation for off-label use and is generally funded when no approved 
therapeutic alternative exists. Schemes allowing pragmatic solutions for the funding 
of off-label use have been recently implemented in France through the granting of 
Temporary Recommendations for Use (RTUs), in Italy through pre-authorisation 
by AIFA (lista farmaci off label), in Germany with the implementation of BfARM 
off-label expert group. Funding through these schemes is granted if evidence of 
treatment success are shown and that there is no therapeutic alternatives. However, 
these schemes do not currently cover all drugs, including IVIgs. There is evidence 
of funding for IVIgs’ off-label use in Spain but no specific schemes are set up. In the 
UK, the Department of Health implemented a Demand Management Programme 
for IVIgs. Their indications are colour-coded according to their level of priority and 
funding is linked to the colour granted. We found that IVIg’s off-label use is funded if 
judged of a high priority. cOnclusiOns: IVIgs’ off-label use funding is not equally 
regarded in the EU5. Harmonisation of off-label use funding, dependant on the level 
of evidence available, may be considered in the future to ensure equal access to IVIg 
therapy amongst European patients.
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